摘要: L’incidence annuelle du cancer sein est estime a 110,3/100 000 dans l’Union europeenne en 2006 [1]. Elle augmente raison de la generalisation depistage et vieillissement population. Bien que mortalite soit baisse avec une survie long terme l’ordre 80 %, le demeure cause importante.
springer.com
sci-hub.st 参考文章(20)
Ligue contre le cancer Comité de la Corrèze, Institut National du Cancer ,(2012)
F. Reyal, J. -Y. Pierga, R. -J. Salmon, A. Vincent-Salomon, M. -A. Bollet, Le point sur les signatures moléculaires dans le cancer du sein Oncologie. ,vol. 12, pp. 263- 268 ,(2010) , 10.1007/S10269-010-1876-9
Early Breast Cancer Trialists' Collaborative Group, None, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials The Lancet. ,vol. 365, pp. 1687- 1717 ,(2005) , 10.1016/S0140-6736(05)66544-0
M.-C Mathieu, R Rouzier, A Llombart-Cussac, L Sideris, S Koscielny, J.P Travagli, G Contesso, S Delaloge, M Spielmann, The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. European Journal of Cancer. ,vol. 40, pp. 342- 351 ,(2004) , 10.1016/J.EJCA.2003.08.015
Aman U. Buzdar, Vicente Valero, Nuhad K. Ibrahim, Deborah Francis, Kristine R. Broglio, Richard L. Theriault, Lajos Pusztai, Marjorie C. Green, Sonja E. Singletary, Kelly K. Hunt, Aysegul A. Sahin, Francisco Esteva, William F. Symmans, Michael S. Ewer, Thomas A. Buchholz, Gabriel N. Hortobagyi, Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen Clinical Cancer Research. ,vol. 13, pp. 228- 233 ,(2007) , 10.1158/1078-0432.CCR-06-1345
Neal S. Goldstein, David Decker, Dawn Severson, Scott Schell, Frank Vicini, Jeffrey Margolis, Nayana S. Dekhne, Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy Cancer. ,vol. 110, pp. 1687- 1696 ,(2007) , 10.1002/CNCR.22981
Mario Campone, Pierre Fumoleau, Emmanuelle Bourbouloux, Pierre Kerbrat, Henri Roché, Taxanes in adjuvant breast cancer setting: which standard in Europe? Critical Reviews in Oncology Hematology. ,vol. 55, pp. 167- 175 ,(2005) , 10.1016/J.CRITREVONC.2005.04.003
Miguel Martin, Tadeusz Pienkowski, John Mackey, Marek Pawlicki, Jean-Paul Guastalla, Charles Weaver, Eva Tomiak, Taher Al-Tweigeri, Linnea Chap, Eva Juhos, Raymond Guevin, Anthony Howell, Tommy Fornander, John Hainsworth, Robert Coleman, Jeferson Vinholes, Manuel Modiano, Tamas Pinter, Shou C. Tang, Bruce Colwell, Catherine Prady, Louise Provencher, David Walde, Alvaro Rodriguez-Lescure, Judith Hugh, Camille Loret, Matthieu Rupin, Sandra Blitz, Philip Jacobs, Michael Murawsky, Alessandro Riva, Charles Vogel, Adjuvant docetaxel for node-positive breast cancer. The New England Journal of Medicine. ,vol. 352, pp. 2302- 2313 ,(2005) , 10.1056/NEJMOA043681
Daniel F Hayes, Ann D Thor, Lynn G Dressler, Donald Weaver, Susan Edgerton, David Cowan, Gloria Broadwater, Lori J Goldstein, Silvana Martino, James N Ingle, I Craig Henderson, Larry Norton, Eric P Winer, Clifford A Hudis, Matthew J Ellis, Donald A Berry, HER2 and Response to Paclitaxel in Node-Positive Breast Cancer The New England Journal of Medicine. ,vol. 357, pp. 1496- 1506 ,(2007) , 10.1056/NEJMOA071167
V. Kataja, M. Castiglione, Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Annals of Oncology. ,vol. 19, pp. 10- ,(2008) , 10.1093/ANNONC/MDP114